SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2003. Spherix Incorporated (formerly Biospherics Incorporated) operates two primary business segments: InfoSpherix (information and telecommunications systems) and BioSpherix (biotechnology, specifically tagatose sweetener licensing). The company is currently engaged in significant legal proceedings regarding its BioSpherix licensing agreement.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Revenue | $4,420,782 | $3,066,168 |
| Net Loss | $(686,388) | $(1,110,724) |
| Loss Per Share (Diluted) | $(0.06) | $(0.10) |
| Cash and Equivalents | $8,923,534 | $9,069,318 |
| Working Capital | $8,269,000 | $8,788,000 (Dec 31, 2002) |
| Bank Line of Credit Outstanding | $1,518,168 | $722,384 (Dec 31, 2002) |
| Net Cash Used in Operating Activities | $(19,277) | $(1,383,270) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 44% ($1.35 million) year-over-year, driven primarily by the InfoSpherix segment. Government contract revenue rose 30%, while commercial contract revenue surged 2,467% due to new contracts initiated in late 2002.
- Improved Profitability: The net loss decreased by approximately 38% compared to the prior year, narrowing from $1.11 million to $686,000.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased by 26% ($276,448). This was largely due to $315,000 in legal fees associated with an ongoing arbitration against Arla Foods amba of Denmark.
- Segment Performance:
- InfoSpherix: Operating loss improved significantly from $769,000 to $66,000.
- BioSpherix: Operating loss widened from $360,000 to $632,000 due to increased legal expenses, despite negligible revenue ($6,000).
- Liquidity: The company utilized its bank line of credit, increasing borrowings by approximately $796,000 during the quarter. Total available credit remaining is $297,487.
Outlook, Risks, and Management Commentary
- Legal Contingency (Arla Foods): The company is in arbitration with Arla Foods regarding delays in commercializing tagatose. To date, $790,000 in legal expenses have been incurred, with significant additional costs expected in 2003. The company seeks damages and acceleration of commercialization.
- Government Contract Risk: The National Park Service (NPS) cancelled the procurement for the National Park Reservation System, a major revenue source. The company plans to file suit in Federal District Court, contesting the non-competitive bundling of the contract. The current contract is extended through September 30, 2003.
- BioSpherix Outlook: Management anticipates tagatose sales could commence by mid-2003 following a joint venture announcement by the licensee. The company is also investing in "Naturlose" (non-food uses of tagatose), funding pilot plant demonstrations.
- Capital Needs: Management believes current cash flow and the bank line of credit are sufficient to meet obligations for the remainder of 2003, even if the credit line is not renewed upon expiration in June 2003.
Investor Verification Checklist
- Arbitration Status: Verify the timeline and potential financial exposure of the arbitration against Arla Foods, including the likelihood of recovering legal fees or securing damages.
- NPS Contract Resolution: Monitor the outcome of the legal challenge regarding the National Park Service reservation system contract and the risk of revenue loss post-September 2003.
- Credit Line Renewal: Confirm the renewal status of the $2 million bank line of credit expiring June 30, 2003, and compliance with tangible net worth covenants.
- Tagatose Commercialization: Assess the progress of the licensee's joint venture and the actual commencement of royalty-generating sales in 2003.
- Commercial Contract Stability: Evaluate the sustainability of the 2,467% increase in commercial InfoSpherix revenue, given management's note that such contracts are sporadic and short-term.